Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model

Anti-Cancer Drugs

Volumn 10, Issue 7, 1999, Pages 671-676

  Platel, Denis ^a   Pouna, Paul ^a   Bonoron Adèle, Simone ^b   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

Author keywords

Cardiotoxicity; Doxorubicin; Idarubicin; Preclinical models

Indexed keywords

DOXORUBICIN; IDARUBICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG UPTAKE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART VENTRICLE PRESSURE; INTRAVENOUS DRUG ADMINISTRATION; ISOLATED HEART; MALE; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032840176     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199908000-00007     Document Type: Article

References (13)

1. 1. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
2. 2. Hollingshead LM, Faulds D. Idarubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 42: 690-719.
3. 3. Casazza AM. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979; 63: 835-44.
4. 4. Martoni A, Piana E, Guaraldi M, et al. Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology 1990; 47: 427-32.
5. 5. Lopez M, Contegiacomo A, Vici P, et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989; 64: 2431-6.
6. 6. Villani F, Galimberti M, Comazzi R, Crippa F. Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). Eur J Cancer Clin Oncol 1989; 25: 13-8.
7. 7. Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827-34.
8. 8. Pouna P, Bonoron-Adèle S, Gouvemeur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996; 117: 1593-9.
9. R) in the conscious rat. Pharmacol Toxicol 1988, 62: 54-6.
10. 10. Minderman H, Buscaglia MD, Rustum YM. Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox). Leukemia 1994; 8: 1401-5.
11. 11. Lorell BH, Wexler LF, Momomura S, Weinberg E, Apstein CS. The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts. Circ Res 1986; 58: 653-63.
12. 12. Baurain R, Deprez-De Campaneere D, Trouet A. Rapid determination of doxorubicin and its fluorescent metabolites by high pressure liquid chromatography. Anal Biochem 1979; 94: 112-6.
13. 13. Looby M, Linke R, Weiss M. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit. Cancer Chemother Pharmacol 1997; 39: 554-6.